DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours
1996

DNA Amplifications in Breast and Ovarian Tumors

Sample size: 1550 publication Evidence: moderate

Author Information

Author(s): F Courjall, M Cuny, C Rodriguez, G Louason, P Speiser, D Katsaros, MM Tanner, R Zeillinger, C Theillet

Primary Institution: Institut de Génétique Moléculaire de Montpellier

Hypothesis

The study aimed to determine the incidence and clinicopathological significance of amplifications at chromosome 20q13 and the MDM2 gene in breast and ovarian tumors.

Conclusion

Both 20q13 and MDM2 amplifications occur preferentially in aggressive breast and ovarian tumors.

Supporting Evidence

  • 20q13 amplification was found in 5.4% of breast tumors and 2.8% of ovarian tumors.
  • MDM2 amplification was found in 5.3% of breast tumors and 3.8% of ovarian tumors.
  • 20q13 amplification correlated with axillary nodal involvement in breast cancer.
  • MDM2 amplification correlated with estrogen receptor positivity in breast cancer.
  • Both amplifications were associated with aneuploidy.

Takeaway

Scientists looked at breast and ovarian cancer samples to see if certain DNA changes were linked to more aggressive forms of cancer. They found that these changes were more common in tougher cases.

Methodology

The study tested 1371 breast and 179 ovarian tumors for DNA amplifications using Southern blotting.

Limitations

The study's findings on correlations were limited by the availability of complete clinical data for all tumors.

Participant Demographics

{"breast_tumors":{"total":1371,"age":{"under_50":307,"over_50":780},"histological_types":{"IDC":954,"ILC":178,"DCIS":15,"other":224}},"ovarian_tumors":{"total":179,"tumor_types":{"serous":84,"mucinous":11,"clear_cell":9,"endometrioid":16,"other":59}}}

Statistical Information

P-Value

0.03

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication